Moreover, research has indicated that dual inhibition of FAK and platelet-derived growth factor receptor-beta (PDGFR-β) synergistically decreases the survival of primary Wilms tumor cells, suggesting potential applications in pediatric renal tumors [36]. Here, PDGFRB is linked to Wilms tumor.